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Abstract 
Objective 
Benzodiazepines (BZDs) are commonly used by chronic pain patients, despite limited evidence of any 
long-term benefits and concerns regarding adverse events and drug interactions, particularly in older 
patients. This article aims to: describe patterns of BZDs use; the demographic, physical, and mental 
health correlates of BZD use; and examine if negative health outcomes are associated with BZD use after 
controlling for confounders. Subjects 
A national sample of 1,220 chronic noncancer pain (CNCP) patients prescribed long-term opioids. 
Methods 
We report on baseline data from a prospective cohort study comparing four groups based on their current 
BZD use patterns. General demographics, pain, mental and physical comorbidity, and health service 
utilization were examined. Results 
One-third (N = 398, 33%) of participants reported BZD use in the past month, and 17% (N = 212) reported 
daily BZD use. BZD use was associated with: 1) greater pain severity, pain interference with life, and lower 
feelings of self-efficacy with respect to their pain; 2) being prescribed “higher-risk” (>200 mg oral 
morphine equivalent) doses of opioids; 3) using antidepressant and/or antipsychotic medications; 4) 
substance use (including more illicit and injection drug use, alcohol use disorder, and daily nicotine use); 
and 5) greater mental health comorbidity. After controlling for differences in demographic characteristics, 
physical and mental health, substance use, and opioid dose, BZD use was independently associated with 
greater past-month use of emergency health care such as ambulance or accident and emergency 
services. Conclusions 
CNCP patients using BZDs daily represent a high-risk group with multiple comorbid mental health 
conditions and higher rates of emergency health care use. The high prevalence of BZD use is inconsistent 
with guidelines for the management of CNCP or chronic mental health conditions. 
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Abstract
Objective. Benzodiazepines (BZDs) are commonly
used by chronic pain patients, despite limited evi-
dence of any long-term benefits and concerns
regarding adverse events and drug interactions, par-
ticularly in older patients. This article aims to:
describe patterns of BZDs use; the demographic,
physical, and mental health correlates of BZD
use; and examine if negative health outcomes
are associated with BZD use after controlling for
confounders.
Subjects. A national sample of 1,220 chronic
noncancer pain (CNCP) patients prescribed long-
term opioids.
Methods. We report on baseline data from a pro-
spective cohort study comparing four groups based
on their current BZD use patterns. General demo-
graphics, pain, mental and physical comorbidity,
and health service utilization were examined.
Results. One-third (N = 398, 33%) of participants
reported BZD use in the past month, and 17%
(N = 212) reported daily BZD use. BZD use was asso-
ciated with: 1) greater pain severity, pain interfer-
ence with life, and lower feelings of self-efficacy with
respect to their pain; 2) being prescribed “higher-
risk” (>200 mg oral morphine equivalent) doses of
opioids; 3) using antidepressant and/or antipsy-
chotic medications; 4) substance use (including
more illicit and injection drug use, alcohol use dis-
order, and daily nicotine use); and 5) greater mental
1
health comorbidity. After controlling for differences
in demographic characteristics, physical and mental
health, substance use, and opioid dose, BZD use
was independently associated with greater past-
month use of emergency health care such as ambu-
lance or accident and emergency services.
Conclusions. CNCP patients using BZDs daily rep-
resent a high-risk group with multiple comorbid
mental health conditions and higher rates of
emergency health care use. The high prevalence
of BZD use is inconsistent with guidelines for the
management of CNCP or chronic mental health
conditions.
Key Words. Chronic Noncancer Pain; Opioid;
Benzodiazepines; Mental Health
Introduction
The prescription of opioids for people with chronic
noncancer pain (CNCP) has increased dramatically in the
United States, Canada, and Australia [1–6]. Benzodiaz-
epine (BZD) use, although common, is reported at much
lower rates in the general population than in chronic pain
populations. A national household survey in the US study
found 4% of respondents reported tranquilizer use and 6%
reported using sleeping pills or other sedative use [7].
General population studies in the UK estimate that 3% of
the population use BZDs [8]. Although there has been
some reduction in BZD use [9,10], BZDs continue
to be prescribed despite there being few indications for
their use.
Significant proportions (18–38%) of CNCP patients are
concurrently prescribed opioids and BZDs [11–13].
Although there are a range of reasons why BZDs may be
prescribed to patients with CNCP, there are few indica-
tions for chronic BZD use specifically in the treatment of
CNCP. One review, conducted two decades ago, iden-
tified a potential role for BZD in acute pain, but there is
little evidence from controlled studies to support their
general use in chronic pain [14]. The exceptions were
just three specific conditions where some evidence of
their efficacy in treating pain was found: chronic tension
headache, temporomandibular disorders, and tic doulou-
reux [14]. Nondrug treatments and other medications
such as antidepressants are considered first-line treat-
ments for chronic anxiety or insomnia, with BZDs
reserved for second-line use when patients are unable to
tolerate first-line medications, or after nondrug treat-
ments have failed [14]. Guidelines state that BZD are
“not recommended” for use in noncancer persistent pain
[15], whereas expert opinion is divided [16]. Although
BZD are effective when used acutely for generalized
anxiety or panic disorders, they are not listed in clinical
guidelines as first-line treatments for these conditions.
These guidelines indicate short-term use, or only where
antidepressants are not tolerated [17,18].
Concurrent use of BZDs and opioids carries potential
risks, particularly in older adults who are more vulnerable
to adverse events and drug interactions [19]. Combined
BZD and opioid use may increase sedation, cognitive and
psychomotor impairment, falls, respiratory depression,
and risk of overdose [20,21]. Chronic BZD and chronic
opioid use are associated with additive effects in
sleep-disordered breathing [22,23] and have the addi-
tional well-known clinical complications of physiological
neuroadaptation with long-term use, and the potential for
development of substance use disorders among some
patients.
Few studies have investigated the possible effects of BZD
use on long-term outcomes for chronic pain patients. One
study of chronic pain patients enrolled in a tertiary pain
clinic found that BZD use was correlated with deteriorating
physical functioning and depression, after controlling for
opioid use [24]. A longitudinal study of older adults found
that new-onset chronic BZD use was predicted by
increasing age, female gender, symptoms of depression,
pain, and poor physical health [25].
Given the potentially serious adverse consequences of
BZD use in chronic pain patients, we examined the preva-
lence and correlates of past, occasional, and daily BZD
use in a sample of CNCP patients who are prescribed
long-term opioid analgesics. Three a priori aims were
defined for these analyses:
1. to describe patterns of BZD use amongst a sample of
CNCP patients prescribed opioids;
2. to examine demographic, physical, and mental health
and substance correlates of BZD use; and
3. to examine if negative health outcomes, including
emergency health care utilization, were independently
associated with BZD use, after controlling for other
patient characteristics.
Methods
Study Design and Setting
The sample comprised 1,220 participants from the base-
line data collected on a prospective cohort study of
persons who have been prescribed opioids for CNCP (the
POINT Study [Pain and Opioids IN Treatment]). The parent
study will collect prospective longitudinal data from this
cohort at four time points over a 2-year follow-up. A
detailed description of the methodology is available else-
where [26].
Eligibility Criteria
POINT participants had to be: 18 years or older; compe-
tent in English; mentally and physically able to complete
telephone and self-complete interviews; without serious
cognitive impairments; living with CNCP (by definition, of
at least 3 months’ duration); prescribed a Schedule 8
opioid (an Australian classification of drugs of dependence
that are subject to additional regulatory controls regarding
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their manufacture, supply, distribution, possession, and
use [27]); and having taken such opioids for CNCP for
more than 6 weeks. Schedule 8 opioids include morphine,
oxycodone, fentanyl, buprenorphine, methadone, hydro-
morphone, and codeine phosphate tablets as a single
ingredient. Schedule 8 does not include tramadol or
codeine in combination with paracetamol.
Patients currently prescribed pharmaceutical opioids for
opioid substitution therapy for heroin dependence and
those taking opioids for cancer pain were ineligible for this
study.
Recruitment
A database of pharmacies and chemists across Australia
and their contact details was purchased in May 2012 [28].
The list included 7,136 pharmacies. After removing dupli-
cates, those that had closed down, or were not
suitable for the study (i.e., located in a hospital or were a
compounding pharmacy), we had a final list of 5,994
pharmacies.
Pharmacies were invited to participate in the study and to
refer eligible participants using a purpose-designed fax
referral form. Pharmacists were asked to approach any
customers who were prescribed a Schedule 8 opioid for
CNCP for a period of greater than 6 weeks.
POINT staff determined the eligibility of interested custom-
ers who were referred to the study, or who contacted the
POINT team. Eligible participants went through a voluntary
informed consent process. After being given details of the
study, those who were willing to participate were booked
in for their initial interview, which was conducted over the
phone and took approximately 1–1.5 hours, and were
sent a self-complete survey in the mail at the same time.
The study was approved by the Human Research Ethics
Committee of the University of New South Wales (HREC
reference: # HC12149).
Interview Procedure
Baseline phone interviews were conducted by trained
interviewers who had previously received suicide assis-
tance training. They had a minimum 3-year health or psy-
chology degree and were provided with glossaries of
chronic pain medications and conditions. Participants
were reimbursed $A40 for the baseline interview.
Measures
Key measures included: demographic characteristics,
current pain (as measured by the Brief Pain Inventory [BPI]
[29]), opioid and BZD use and/or dependence (using Inter-
national Statistical Classification of Diseases and Related
Health Problems 10th Revision [ICD-10] dependence cri-
teria assessed via the Composite International Diagnostic
Interview [CIDI] [30]) pain self-efficacy (using the Pain Self-
Efficacy Questionnaire [PSEQ] [31,32]), health service uti-
lization, alcohol and illicit drug use, and depression and
generalized anxiety disorder (GAD; as measured by the
Patient Health Questionnaire-9 [PHQ-9] and GAD gener-
alized anxiety disorder-7 modules of the Patient Health
Questionnaire [33]). Previously validated cut-offs were
used for screening tools as follows: symptoms indicating
major depressive disorder were defined at a score of ≥10
on the PHQ-9 [34], symptoms of moderate to severe
anxiety were defined as a score of ≥10 on the GAD-7 [35].
A score of ≥3 on the Primary Care Post Traumatic Stress
Disorder screen (PC-PTSD) was used to indicate pres-
ence of PTSD [36].
Weekly income was classified as greater or less than
$A400/week, with less than $AUD400/week comparable
with unemployment or disability benefits.
In addition to reporting the number of days on which each
medication was used in the past month, participants were
also asked to return a medication diary that reported all
medication taken over a 7-day period. Of the 1,220 par-
ticipants, 853 had medication diaries available for analysis.
Where BZD doses were reported, these data only repre-
sent the subset of patients that returned the medication
diary. Oral morphine equivalent daily doses were calcu-
lated using available references [15,37–39]. A “high risk”
opioid dose variable was created, which was defined as
more than 200 mg/day oral morphine equivalents [40,41].
Data Analysis
We defined four distinct BZD use groups: patients who
had used BZDs every day for the past month (referred to
as “Current Daily” users throughout) (N = 212), those who
had used BZDs less than daily in the past month (referred
to as “Current Less Than Daily”) (N = 186), those who had
used BZDs previously but not in the past month (referred
to as “Past BZD Use”) (N = 372), and those who had never
used BZDs (referred to as “Never BZD Use”) (N = 450).
Multinomial regression was used to compare the four use
groups. Medians and nonparametric statistics were used
to compare groups where the distribution was non-
normal. Analysis of covariance was used to examine
whether pain self-efficacy differed between the BZD use
groups, after controlling for pain severity as the covariate.
Multivariate logistic regression models were used to deter-
mine whether patterns of BZD use were independently
associated with ambulance and accident and emergency
attendance, after controlling for differences between the
BZD use groups identified through univariate analyses.
Results
BZD Use Patterns
Four hundred fifty participants (36.9%) reported never
having used a BZD (“Never BZD Use”). Three hundred
seventy-two (30.5%) reported past BZD use only (“Past
BZD Use”), 186 (15.2%) reported current less than daily
use (“Current Less Than Daily”), and 212 reported current
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daily use (“Current Daily”) in the past month (17.3%;
Table 1). Of those currently using BZDs (N = 398), 53%
were using them daily.
Those reporting current less than daily BZD use had used
BZDs on a mean of 8.2 days in the previous 28 days
(standard deviation [SD] 6.8, range 1–25 days). Multino-
mial logistic regression did not detect a significant differ-
ence in age of first BZD use between the groups: the
mean age of first use for the Past BZD Use group was
38.8 years (SD 14.7 years), 39.7 years (SD 15.1 years) for
the current less than daily group, and 40.4 years (SD 16.8
years) for the current daily group.
Sixty-two people (5.1% of the sample) endorsed the CIDI
BZD screening question (i.e., “was ever used so regularly
that they could not stop using the sedative or tranquilizer
prescribed” to them) and were further assessed using the
CIDI for a BZD use disorder (using ICD-10 criteria). Those
using BZDs daily in the past month were more likely to
meet criteria for a BZD use disorder (8.5%, N = 18, odds
ratio [OR]: 3.36, 95% confidence interval [CI]: 0.152–7.42)
than past BZD users (2.7%, N = 10).
Demographic Differences by BZD Use Group
Participants who reported any BZD use were younger
than those in the Never BZD Use (reference) group
(Table 1). Current daily BZD users reported lower levels of
current employment/study compared with the Never BZD
use reference group.
Types of BZDs Used
Diazepam was the most common BZD reported by the
subset of participants that used a BZD in the past month
and returned a medication diary (N = 254). Its use was
reported by 48% (N = 122, mean daily dose 9.1 mg, SD
8.8 mg), followed by temazepam (22%, N = 56, mean
daily dose 10.3 mg, SD 7.0 mg), oxazepam (12%, N = 30,
mean daily dose 28.4 mg, SD 14.4 mg), nitrazepam (10%,
N = 25, mean daily dose 6.9 mg, SD 7.6 mg),
alprazolam(5%, N = 12, mean daily dose 2.0 mg, SD
1.8 mg), and clonazepam (5%, N = 12, mean daily dose
2.4 mg, SD 2.75 mg). A small number of participants also
reported use of BZD-like drugs zopiclone (N = 8) and
zolpidem (N = 11). Twenty-nine (11%) reported using two
BZDs in the same week, and two participants (1%)
reported using three BZDs in the same week.
Aberrant BZD Use
Participants were asked if they had ever used BZDs in a
range of unsanctioned ways. Of those who had ever used
BZDs (N = 770), 5.5% (N = 42) reported ever using
someone else’s BZDs, and 4.5% (N = 35) reported using
their own prescribed BZDs in a way that was not as
prescribed, (i.e., injected, or used for recreational pur-
poses). Having ever used someone else’s BZDs was
reported by more of those currently using BZDs less than
daily (8.1%, OR: 2.26, 95% CI: 1.07–4.78), compared Ta
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with past BZD users (Reference category, 3.8%). The
difference was not significant between past and daily BZD
users (6.3%, OR: 1.72, 95% CI: 0.79–3.74). Those using
BZDs daily were more likely to report recreational or
intravenous use (7.8%, OR: 2.15, 95% CI: 1.03 – 4.51)
compared with past BZD users (3.8%) and less than daily
BZD users (2.7%, OR: 0.71, 95% CI: 0.25–2.00).
Pain
There was no difference in the duration of pain experience,
or of duration of opioid prescription between the groups,
although BZD users had received their first opioid pre-
scription at a younger age than those who did not report
using BZDs. The types of pain conditions reported within
the past 12 months were broadly comparable across the
three categories of BZD use groups, except that the
current daily BZD use group reported the highest mean
number of pain conditions. The current daily BZD use
group reported the highest Pain Severity and Pain Inter-
ference scores on the BPI.
Any BZD use (past or current) was associated with
poorer pain self-efficacy (i.e., less confidence in their
ability to do a range of activities including household
chores, socializing, work, and to cope with their pain) as
measured with the Pain Self-Efficacy Questionnaire,
where lower scores reflect poorer self-reported efficacy
in managing pain. The current daily use group had the
lowest pain self-efficacy scores (see Table 2). BZD use
was independently associated with significantly lower
mean pain self-efficacy scores after controlling for pain
severity (F(2, 1127) = 14.86, P < 0.001). Adjusted means
for the pain self-efficacy score were 31.8 (SD 12.3) for
the Never BZD Use group, 29.4 (SD 18.8) for the Past
BZD Use group, 27.5 (SD 8.5) for the Current Less Than
Daily group, and 25.6 (SD 12.9) for the Current Daily Use
group. The lower level of self-efficacy in the daily use
group compared with the Never BZD Use group was of
moderate magnitude (Hedges’ g = 0.49). Differences
between other groups were either small (poorer self-
efficacy in the Less Than Daily group compared with
Never Use, g = 0.37) or not meaningful (all others
g < 0.22).
Other Medication Use
A higher proportion of BZDs users had been also pre-
scribed antidepressant and/or antipsychotic medication
(Table 2). Two-thirds (68.4%) of the current daily use group
had used antidepressants and 11.2% had used an anti-
psychotic medication in the past month, compared with
44.9% and 3.1% in the Never BZD Use group.
Participants who had used BZDs were also prescribed
more opioids and reported a greater median opioid
dose. We examined the proportion of each group pre-
scribed a “high risk” opioid dose (>200 mg/day oral mor-
phine equivalents). The two current BZD use groups
(Daily and Less Than Daily) had higher proportions of
“high risk” opioid doses in past month (21.4% in the
Current Less Than Daily and 27.9% in Current Daily
BZD use) compared with 8.9% in Never BZD Use
group).
Substance Use and Mental Health
BZD users were more likely to report lifetime illicit drug
use, injection drug use, and an alcohol use disorder (using
ICD-10 definitions) than those who had never used BZDs
(Table 3). Current daily nicotine use was more likely among
current BZD users (whether using daily or less than daily)
compared with those who had never used BZDs.
Most BZD users reported a lifetime diagnosis or develop-
ment of a mental health condition, and a more mental
health conditions than nonusers (Table 3). BZD users
reported more symptoms of moderate to severe depres-
sion, anxiety, and were more likely to meet criteria for
PTSD and past month panic attacks. The daily BZD use
group had the highest proportion reporting symptoms that
met criteria for each of these conditions (Table 3).
BZD Use and Emergency Health Service Utilization
At a univariate level, the daily BZD use group reported
more visits to the general practitioner in the past month
and were more likely to use emergency health care com-
pared with those who had never used BZDs. Those who
reported daily BZD use were more likely to have used an
ambulance in the past month (OR: 2.7, 95% CI: 1.12–
6.41) and more likely to have attended a hospital emer-
gency department (OR: 2.01, 95% CI: 1.06–3.81) than
those who had not used BZDs, after controlling for differ-
ences in age, gender, income, number of pain and other
chronic conditions, moderate to severe anxiety and
depression symptoms and history of illicit drug use and
drug injection, and receiving a “high risk dose” of opioids.
The three BZD use groups were more likely to report a
lifetime drug overdose compared with the group that had
never used BZDs.
Discussion
In this national sample of CNCP patients-prescribed
opioids, approximately one-third (33%) had used a BZD in
the previous month and half of those (53%) reported daily
BZD use. Although a high proportion of these CNCP
patients reported using BZDs regularly, most participants
reported using only one type of BZD. This was most often
diazepam, temazepam, oxazepam, or nitrazepam, which
jointly accounted for approximately 90% of all recent BZD
use. These are the most commonly utilized BZDs
in routine prescribing data for the general Australian
population [9].
The mean self-reported BZD doses used were within
therapeutic norms, and few participants reported aberrant
BZD use. Nearly one in 10 (9%) of current daily BZD users
met diagnostic criteria for a lifetime BZD use disorder,
compared with below 3% in all other groups. In short,
although many patients had recently used BZDs, there
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was little evidence of patients using them other than as
prescribed and few endorsed criteria for substance use
disorder or reported nonmedical use.
Nonetheless, the high rates of BZD use in this population
are at odds with clinical guidelines that do not recommend
the long-term prescription of BZDs for the vast majority of
chronic pain or mental health conditions. Few patients
suffered from the short list of chronic pain conditions for
which BZDs may have some therapeutic role [14].
Although being unable to tolerate antidepressants is iden-
tified as a possible indication for using BZDs [17], the large
number of patients concurrently prescribed antidepres-
sants and BZDs suggests that this is not the reason for
BZD use.
BZD use in this sample was broadly associated with three
factors: 1) pain (including number and type of pain con-
ditions, greater self-reported recent pain severity and pain
interference, and poorer pain self-efficacy), 2) mental dis-
orders (including current depression and generalized
anxiety disorder); and 3) substance use (including alcohol
use disorders, tobacco use, injecting drug use, and illicit
drug use).
One way of understanding the high prevalence of BZD
use in this sample is to consider how CNCP patients
who use BZD might differ from other patients in their
approach to treatment. Daily BZD users reported the
highest levels of current antidepressant and antipsy-
chotic medications, were more likely to be taking high
opioid doses (>200 mg oral morphine equivalent mg
daily), and reported the lowest self-efficacy in managing
their pain. BZD users also reported higher rates of
alcohol and other illicit drug use. In summary, BZD users
also used more prescribed and recreational drugs that
may suggest a pattern of “chemical coping” [42] or may
reflect the high levels of substance use and comorbid
mental disorders in this group.
It is unclear whether the greater use of medication and
other substances among BZD users is in response to, or
contributes to more severe pain and psychological dis-
tress. Alternatively, it may be that current approaches to
pain treatment using opioid medications and antidepres-
sants fail to satisfactorily address these patients’ pain
and distress, and so that higher opioid doses and a
wider variety of medications are used in an attempt to
achieve better pain relief. This raises the value of com-
prehensive approaches to pain management that
broadly address the range of biopsychosocial aspects of
chronic pain and reduce reliance upon psychoactive
medication for symptom control as the predominant
intervention [43,44]. Indeed, the triple comorbidities of
chronic pain, mental health, and substance use disor-
ders highlight the many needs of this patient population.
The complexity of the population not only demands a
multifaceted rather than only a medication-based
approach to pain, but also suggests the need for addi-
tional strategies that may address patients’ mental health
or substance use problems.
Those using BZDs generally reported poorer health out-
comes, greater utilization of health services, and in par-
ticular greater use of emergency services such as
ambulance, emergency department presentations, and a
higher likelihood of having a history of accidental overdose
than those who did not use BZDs. A history of overdose
was reported in approximately a quarter of daily BZD
users (compared with 10% of non-BZD users). The high
rates of polypharmacy are of particular concern, especially
in older patients who are more vulnerable to drug interac-
tions and related adverse events.
The high prevalence of BZD use in CNCP is an issue that
requires more clinical and research attention in light of the
limited number of accepted indications for long-term BZD
prescribing for either pain or mental health conditions and
the poorer health outcomes in these patients. Although it
is not possible from this cross-sectional study design to
identify whether BZD use is safe, effective, or appropriate
in CNCP patients, the high prevalence of BZD use is
clearly inconsistent with therapeutic guidelines recom-
mendations on the management of CNCP or chronic
mental health conditions. This raises questions about the
adequacy of the assessment and clinical decision making
in these patients. There have been many approaches to
identifying high risk CNCP patients in whom opioid medi-
cation should be used cautiously [41], where a personal or
family history of substance abuse is a constant theme. We
are unaware of similar approaches to identifying risk
factors for BZD use in CNCP patients.
There are some study limitations that need to be consid-
ered. Although a clear strength of the study was that all
Australian community pharmacies were approached and
many assisted with recruitment, we have limited data on
those pharmacists and patients who did not participate.
Furthermore, we rely on self-report data which, while
being generally reliable when there are no disincentives for
being honest [45], may be subject to biases. All partici-
pants were informed that their responses would be
de-identified and confidential, which traditionally results in
more valid reports of substance use [46]. Furthermore, we
do not know the indications for each of the medications
used by participants. Future work that can explore
reasons for BZD initiation and continued use in these
patients would be a valuable addition to the literature.
Finally, as this is a cross-sectional analysis, we are not able
to assess causality. We do not know what the outcomes
for these patients would have been had they not been
prescribed BZDs. The longer term findings for this study
will provide important data on outcomes for those that use
BZDs over time.
This study identified a high prevalence of BZD use in
CNCP patients, with approximately one-third of patients
reporting use within the past month. CNCP patients with
daily BZD use represent a highly distressed group of
patients: they reported greater pain severity and more
interference with daily life, multiple mental health prob-
lems, and a higher rate of substance use disorders. They
are at risk of adverse events from polypharmacy and
8
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report higher rates of emergency health care use and
opioid-related overdose. Careful consideration needs to
be given to the role of BZDs in the treatment of CNCP, and
there is a need for ongoing monitoring of BZD use. In light
of the current concerns with opioid-related harms, those
using opioids and BZDs appear to represent a particularly
high-risk group.
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